Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,
UK biotech Autifony has signed an exclusive licensing deal with Jazz Pharmaceuticals, giving the Ireland-headquartered drugmaker global rights to a pair of ion channel tar
Jazz Pharma's $325 million gamble on rights to Zymeworks' HER2-directed bispecific antibody zanidatamab was the largest in its history, and seems like a safer bet after a mid-stage readout
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl